A O O O O
team O O O O
of O O O O
researchers O O O O
led O O O O
by O O O O
scientists O O O O
at O O O O
the O O O O
University O O O O
of O O O O
Georgia O O O O
and O O O O
the O O O O
[Cincinnati O O O O
Children's O O O O
Hospital O O O O
Medical O O O O
Center](https://www.cincinnatichildrens.org/) O O O O
are O O O O
near O O O O
the O O O O
completion O O O O
of O O O O
a O O O O
phase O O O O
1 O O O O
clinical O O O O
trial O O O O
for O O O O
a O O O O
new O O O O
single-dose O O O O
intranasal O O O O
COVID O O O O
vaccine. O O O O
Unlike O O O O
traditional O O O O
vaccines O O O O
that O O O O
require O O O O
an O O O O
injection, O O O O
this O O O O
vaccine O O O O
is O O O O
administered O O O O
through O O O O
a O O O O
nasal O O O O
spray O O O O
similar O O O O
to O O O O
those O O O O
commonly O O O O
used O O O O
to O O O O
vaccinate O O O O
against O O O O
influenza. O O O O
A O O O O
fine O O O O
mist O O O O
inhaled O O O O
through O O O O
the O O O O
nostrils O O O O
allows O O O O
the O O O O
vaccine O O O O
to O O O O
target O O O O
the O O O O
mucosal O O O O
cells O O O O
that O O O O
line O O O O
the O O O O
nasal O O O O
passages O O O O
and O O O O
airways. O O O O
Phase O O O O
1 O O O O
clinical O O O O
trials O O O O
were O O O O
conducted O O O O
at O O O O
four O O O O
sites O O O O
in O O O O
Kentucky, O O O O
New O O O O
York, O O O O
Ohio, O O O O
and O O O O
Texas. O O O O
The O O O O
trials O O O O
are O O O O
based O O O O
on O O O O
encouraging O O O O
preclinical O O O O
results O O O O
reported O O O O
in O O O O
the O O O O
peer-reviewed O O O O
journal O O O O
[Science O O O O
Advances.](https://www.science.org/journal/sciadv) O O O O
"We O O O O
have O O O O
been O O O O
developing O O O O
this O O O O
vaccine O O O O
platform O O O O
for O O O O
more O O O O
than O O O O
20 O O O O
years, O O O O
and O O O O
we O O O O
began O O O O
working O O O O
on O O O O
new O O O O
vaccine O O O O
formulations O O O O
to O O O O
combat O O O O
COVID-19 O O O O
during O O O O
the O O O O
early O O O O
days O O O O
of O O O O
the O O O O
pandemic," O O O O
says O O O O
Biao O O O O
He, O O O O
a O O O O
professor O O O O
in O O O O
UGA's O O O O
[Department O O O O
of O O O O
Infectious O O O O
Diseases](https://vet.uga.edu/education/academic-departments/infectious-diseases/) O O O O
in O O O O
the O O O O
[ O O O O
College O O O O
of O O O O
Veterinary O O O O
Medicine](https://vet.uga.edu/). O O O O
"Our O O O O
preclinical O O O O
data O O O O
show O O O O
that O O O O
this O O O O
vaccine O O O O
not O O O O
only O O O O
protects O O O O
against O O O O
infection O O O O
but O O O O
also O O O O
significantly O O O O
reduces O O O O
the O O O O
chances O O O O
of O O O O
transmission." O O O O
The Reason 5 O O
Advantages Reason 5 O O
of Reason 5 O O
Nasal Reason 5 O O
Spray Reason 5 O O
Vaccines Reason 5 O O
He Reason 5 O O
and Reason 5 O O
his Reason 5 O O
collaborators Reason 5 O O
developed Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
by Reason 5 O O
inserting Reason 5 O O
a Reason 5 O O
portion Reason 5 O O
of Reason 5 O O
the Reason 5 O O
SARS-CoV-2 Reason 5 O O
spike Reason 5 O O
protein Reason 5 O O
into Reason 5 O O
another Reason 5 O O
virus Reason 5 O O
known Reason 5 O O
as Reason 5 O O
parainfluenza Reason 5 O O
virus Reason 5 O O
5, Reason 5 O O
or Reason 5 O O
PIV5, Reason 5 O O
which Reason 5 O O
is Reason 5 O O
thought Reason 5 O O
to Reason 5 O O
contribute Reason 5 O O
to Reason 5 O O
upper Reason 5 O O
respiratory Reason 5 O O
infections Reason 5 O O
in Reason 5 O O
dogs Reason 5 O O
but Reason 5 O O
is Reason 5 O O
completely Reason 5 O O
harmless Reason 5 O O
to Reason 5 O O
humans. Reason 5 O O
The Reason 5 O O
modified Reason 5 O O
PIV5 Reason 5 O O
virus Reason 5 O O
acts Reason 5 O O
as Reason 5 O O
a Reason 5 O O
delivery Reason 5 O O
vehicle Reason 5 O O
that Reason 5 O O
produces Reason 5 O O
proteins Reason 5 O O
found Reason 5 O O
in Reason 5 O O
the Reason 5 O O
coronavirus Reason 5 O O
and Reason 5 O O
prompts Reason 5 O O
the Reason 5 O O
immune Reason 5 O O
system Reason 5 O O
to Reason 5 O O
mount Reason 5 O O
a Reason 5 O O
defenseâ€”ultimately Reason 5 O O
promoting Reason 5 O O
immunity Reason 5 O O
to Reason 5 O O
infection. Reason 5 O O
Most Reason 5 O O
people Reason 5 O O
contract Reason 5 O O
COVID-19 Reason 5 O O
through Reason 5 O O
droplets Reason 5 O O
from Reason 5 O O
infected Reason 5 O O
individuals Reason 5 O O
when Reason 5 O O
they Reason 5 O O
cough Reason 5 O O
or Reason 5 O O
sneeze. Reason 5 O O
Those Reason 5 O O
droplets Reason 5 O O
go Reason 5 O O
into Reason 5 O O
a Reason 5 O O
person's Reason 5 O O
upper Reason 5 O O
airways, Reason 5 O O
and Reason 5 O O
that's Reason 5 O O
where Reason 5 O O
the Reason 5 O O
virus Reason 5 O O
begins Reason 5 O O
replicating Reason 5 O O
so Reason 5 O O
it Reason 5 O O
can Reason 5 O O
spread Reason 5 O O
throughout Reason 5 O O
the Reason 5 O O
lungs Reason 5 O O
and Reason 5 O O
other Reason 5 O O
parts Reason 5 O O
of Reason 5 O O
the Reason 5 O O
body. Reason 5 O O
"This Reason 5 O O
vaccine Reason 5 O O
targets Reason 5 O O
those Reason 5 O O
areas Reason 5 O O
specifically Reason 5 O O
and Reason 5 O O
creates Reason 5 O O
lasting Reason 5 O O
immunity Reason 5 O O
at Reason 5 O O
the Reason 5 O O
site Reason 5 O O
of Reason 5 O O
infection," Reason 5 O O
says Reason 5 O O
Mark Reason 5 O O
Tompkins, Reason 5 O O
professor Reason 5 O O
of Reason 5 O O
infectious Reason 5 O O
diseases Reason 5 O O
at Reason 5 O O
UGA Reason 5 O O
and Reason 5 O O
a Reason 5 O O
member Reason 5 O O
of Reason 5 O O
the Reason 5 O O
research Reason 5 O O
team. Reason 5 O O
Dan O O O O
Wagner, O O O O
a O O O O
clinical O O O O
trial O O O O
volunteer O O O O
from O O O O
Cincinnati, O O O O
told O O O O
USA O O O O
Today O O O O
that O O O O
he O O O O
had O O O O
experienced O O O O
no O O O O
side O O O O
effects O O O O
and O O O O
that O O O O
he's O O O O
hopeful O O O O
about O O O O
the O O O O
vaccine. O O O O
"I O O O O
wanted O O O O
a O O O O
vaccine O O O O
that O O O O
protects O O O O
other O O O O
people O O O O
too, O O O O
not O O O O
just O O O O
myself," O O O O
Wagner O O O O
said. O O O O
Promising Reason 5 O O
results Reason 5 O O
Previous Reason 5 O O
studies Reason 5 O O
showed Reason 5 O O
that Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
produced Reason 5 O O
a Reason 5 O O
localized Reason 5 O O
immune Reason 5 O O
response, Reason 5 O O
involving Reason 5 O O
antibodies Reason 5 O O
and Reason 5 O O
cellular Reason 5 O O
immunity, Reason 5 O O
that Reason 5 O O
completely Reason 5 O O
protected Reason 5 O O
mice Reason 5 O O
from Reason 5 O O
fatal Reason 5 O O
doses Reason 5 O O
of Reason 5 O O
SARS-CoV-2. Reason 5 O O
The Reason 5 O O
vaccine Reason 5 O O
also Reason 5 O O
prevented Reason 5 O O
infection Reason 5 O O
in Reason 5 O O
ferrets Reason 5 O O
and, Reason 5 O O
importantly, Reason 5 O O
appeared Reason 5 O O
to Reason 5 O O
block Reason 5 O O
transmission Reason 5 O O
of Reason 5 O O
COVID-19 Reason 5 O O
between Reason 5 O O
animals. Reason 5 O O
The O O O O
vaccine O O O O
used O O O O
in O O O O
the O O O O
trial O O O O
only O O O O
requires O O O O
a O O O O
single O O O O
dose, O O O O
and O O O O
it O O O O
can O O O O
be O O O O
stored O O O O
at O O O O
normal O O O O
refrigerator O O O O
temperatures O O O O
for O O O O
up O O O O
to O O O O
three O O O O
months, O O O O
He O O O O
said. O O O O
Because O O O O
it O O O O
is O O O O
given O O O O
intranasally, O O O O
the O O O O
vaccine O O O O
is O O O O
also O O O O
easier O O O O
to O O O O
administer, O O O O
especially O O O O
for O O O O
those O O O O
with O O O O
a O O O O
fear O O O O
of O O O O
needles. O O O O
Previous Reason 3 O O
studies Reason 3 O O
showed Reason 3 O O
the Reason 3 O O
vaccine Reason 3 O O
platform Reason 3 O O
completely Reason 3 O O
protects Reason 3 O O
experimental Reason 3 O O
animals Reason 3 O O
from Reason 3 O O
another Reason 3 O O
dangerous Reason 3 O O
coronavirus, Reason 3 O O
Middle Reason 3 O O
Eastern Reason 3 O O
Respiratory Reason 3 O O
Syndrome. Reason 3 O O
The Reason 3 O O
disease, Reason 3 O O
also Reason 3 O O
known Reason 3 O O
as Reason 3 O O
MERS, Reason 3 O O
was Reason 3 O O
first Reason 3 O O
reported Reason 3 O O
in Reason 3 O O
Saudi Reason 3 O O
Arabia Reason 3 O O
in Reason 3 O O
2012. Reason 3 O O
"We O O O O
are O O O O
all O O O O
very O O O O
fortunate O O O O
to O O O O
have O O O O
a O O O O
team O O O O
of O O O O
dedicated O O O O
scientists O O O O
who O O O O
made O O O O
the O O O O
development O O O O
of O O O O
this O O O O
vaccine O O O O
possible," O O O O
He O O O O
says. O O O O
"We O O O O
are O O O O
eager O O O O
to O O O O
see O O O O
the O O O O
results O O O O
from O O O O
the O O O O
phase O O O O
1 O O O O
clinical O O O O
trial, O O O O
and O O O O
we O O O O
want O O O O
to O O O O
move O O O O
this O O O O
technology O O O O
forward O O O O
as O O O O
fast O O O O
as O O O O
possible O O O O
so O O O O
that O O O O
we O O O O
can O O O O
help O O O O
control O O O O
the O O O O
COVID-19 O O O O
pandemic." O O O O
This O O O O
research O O O O
was O O O O
supported O O O O
by O O O O
[CyanVac](https://www.cyanvacllc.com/), O O O O
a O O O O
startup O O O O
company O O O O
developing O O O O
vaccines O O O O
based O O O O
on O O O O
the O O O O
PIV5 O O O O
technology. O O O O
The O O O O
company O O O O
is O O O O
supported O O O O
by O O O O
[Georgia O O O O
Research O O O O
Alliance](https://gra.org/) O O O O
and O O O O
is O O O O
based O O O O
in O O O O
the O O O O
University O O O O
of O O O O
Georgia's O O O O
business O O O O
incubator. O O O O
This O O O O
story O O O O
will O O O O
appear O O O O
in O O O O
the O O O O
Fall O O O O
2022 O O O O
issue O O O O
of O O O O
Georgia O O O O
Magazine O O O O
